Anlon Healthcare reported strong Q1FY27 results with 163% revenue growth to ₹87.62 Cr and 133% PAT growth to ₹8.28 Cr. The company expanded into Finished Dosage Formulations via subsidiary acquisition.
Anlon Healthcare has incorporated a new subsidiary, "ANLON BIOLOGICS PRIVATE LIMITED," to manufacture surgical implants and medical devices, aiming to expand its pain management segment.
Anlon Healthcare has incorporated a new subsidiary, Anlon Medicare Private Limited, to manufacture surgical implants and medical devices. This move aims to strategically complement and expand its pain management business. Initial investment is Rs. 11 Lakhs for 55% shareholding.
Anlon Healthcare CMD shared business performance, industry outlook, growth plans, and CAPEX details in a recent podcast. No UPSI was disclosed.
Anlon Healthcare reports strong FY26 results with revenue up 43% to ₹172.22 Cr. Strategic acquisitions of Bizotic Lifescience and Apiqo Organics strengthen its manufacturing and backward integration capabilities.
